Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023–24: a modelling study

Respiratory syncytial virus (RSV) is a major cause of hospitalisations and deaths among infants worldwide. France was one of the first countries to implement a national programme (beginning on Sept 15, 2023) for administration of nirsevimab, a single-dose long-acting monoclonal antibody treatment, t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet child & adolescent health 2024-10, Vol.8 (10), p.721-729
Hauptverfasser:	Brault, Antoine, Pontais, Isabelle, Enouf, Vincent, Debeuret, Christine, Bloch, Emma, Paireau, Juliette, Rameix-Welti, Marie-Anne, White, Michael, Baudemont, Gaëlle, Lina, Bruno, Parent du Châtelet, Isabelle, Casalegno, Jean-Sébastien, Vaux, Sophie, Cauchemez, Simon
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - therapeutic use Antiviral Agents - therapeutic use Bronchiolitis - drug therapy Bronchiolitis - epidemiology Bronchiolitis - prevention & control Bronchiolitis, Viral - drug therapy Bronchiolitis, Viral - epidemiology Bronchiolitis, Viral - prevention & control Female France - epidemiology Hospitalization - statistics & numerical data Human health and pathology Humans Infant Infant, Newborn Infectious diseases Life Sciences Male Pharmaceutical sciences Pharmacology Respiratory Syncytial Virus Infections - drug therapy Respiratory Syncytial Virus Infections - epidemiology Respiratory Syncytial Virus Infections - prevention & control Respiratory Syncytial Virus, Human Retrospective Studies Santé publique et épidémiologie
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!